DEF: Perrigo Sets Date for 2025 Annual General Meeting, Outlines Key Proposals

Perrigo announces its 2025 Annual General Meeting (AGM) will be held on May 1, 2025, featuring proposals on director elections, auditor ratification, executive compensation, and more.

Summary

• Perrigo will hold its 2025 Annual General Meeting (AGM) on May 1, 2025, in Dublin, Ireland.
• Shareholders as of the record date, March 3, 2025, are eligible to vote.
• The AGM agenda includes the election of eleven director nominees, ratification of Ernst & Young LLP as the independent auditor, and advisory approval of executive compensation.
• Other proposals include renewing the Board's authority to issue shares and opt-out of statutory pre-emption rights under Irish law, increasing the maximum number of directors, and approving amendments to the Company's Articles of Association.
• Proposals 1-4 and 6 require a simple majority, while Proposals 5 and 7 need 75% approval.
• The company achieved full-year adjusted EPS within its communicated guidance range, delivered mid-single-digit adjusted operating income growth and expanded adjusted operating margin in 2024.
• Project Energize streamlining efforts achieved annual gross savings of $139 million in 2024 and the Company remains on track to achieve its annual gross savings target of $140 million to $170 million by the end of 2026.
• Reported net sales were $4.4 billion compared to $4.7 billion, due primarily to actions to augment and strengthen the infant formula business.
• Adjusted operating income increased $35 million to $0.6 billion, higher by 6% compared to the prior year.
• Adjusted operating margin of 13.9% expanded 160 basis points compared to the prior year.
• Adjusted earnings per share of $2.57, compared to $2.58 in the prior year.
• Operating cash flow was $363 million, leading to net cash from operating activities as a percentage to adjusted diluted net income of 102%, and ended the year with cash and cash equivalents on the balance sheet of $559 million.
• Net leverage to adjusted EBITDA decreased to 4.0x at the end of 2024, down from 4.5x at the prior year end.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both positive financial results and strategic initiatives alongside challenges and areas for improvement. The overall tone is optimistic, focusing on future growth and shareholder value.

Positives

• The company achieved full-year adjusted EPS within its communicated guidance range in 2024.
• Adjusted operating income increased by $35 million to $0.6 billion, a 6% increase year-over-year.
• Adjusted operating margin expanded by 160 basis points to 13.9% in 2024.
• Operating cash flow was $363 million, with net cash from operating activities at 102% of adjusted diluted net income.
• The company de-risked its balance sheet, reducing net leverage to adjusted EBITDA to 4.0x from 4.5x the prior year.
• Project Energize streamlining efforts achieved annual gross savings of $139 million in 2024 and the Company remains on track to achieve its annual gross savings target of $140 million to $170 million by the end of 2026.

Negatives

• Reported net sales decreased from $4.7 billion to $4.4 billion, primarily due to actions to augment and strengthen the infant formula business.
• Adjusted earnings per share decreased slightly from $2.58 to $2.57.

Risks

• The evolving U.S. regulatory environment within the infant formula industry impacted the infant formula business during the year.
• The company's performance fell short of net sales, earnings, cash flow and gross margin targets in the Annual Incentive Plans or 'AIP'.

Future Outlook

The company is prioritizing high-growth brands, amplifying R&D, bolstering capabilities and directing resources where they matter most.

Industry Context

The announcement reflects standard corporate governance practices for publicly traded companies, particularly those incorporated in Ireland, and highlights the company's focus on shareholder engagement and long-term value creation within the consumer self-care market.

Comparison to Industry Standards

• The executive compensation practices, including the use of peer groups (Bausch Health Companies Inc, Campbell Soup Company, Church & Dwight Co., Inc., Clorox Company, Coty Inc., Edgewell Personal Care Company, Hain Celestial Group, Inc., Haleon plc, Helen of Troy Ltd., Herbalife Nutrition Ltd., Kenvue Inc., McCormick & Co. Inc, Nu Skin Enterprises, Inc., Post Holdings, Inc., Prestige Consumer Healthcare, Inc., Reckitt Benckiser Group plc, Spectrum Brands Holdings, Inc TreeHouse Foods, Inc.) and performance-based incentives, are consistent with industry standards.
• The focus on ESG initiatives aligns with increasing investor expectations for corporate responsibility.
• The company's financial performance, including adjusted EPS and operating income growth, is a key indicator of its competitiveness within the consumer self-care market.

Management Changes

Stakeholder Impact

• Shareholders: The AGM provides an opportunity to vote on key decisions and influence the company's direction.
• Employees: The document outlines executive compensation and talent management strategies.
• Customers: The company's focus on consumer self-care and accessible health solutions impacts product availability and quality.
• Suppliers: Responsible sourcing practices and supply chain reinvention programs affect supplier relationships.
• Creditors: The company's financial performance and debt management impact creditworthiness.

Next Steps

• Shareholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual General Meeting on May 1, 2025.
• The Board will consider the results of the advisory vote on executive compensation for future decisions.

Key Dates

Keywords

Annual General Meeting, Executive Compensation, Board of Directors, Shareholders, Perrigo, Governance, Financials